| Wang, Xian |
NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
|
|
| Recruiting | 3 | 256 | US, RoW | Afuresertib, Fulvestrant, Afuresertib/placebo | Laekna Limited | Breast Cancer | 10/26 | 12/26 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
NCT05439629: Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | BAT5906 injection, Lucentis | Bio-Thera Solutions | Neovascular (Wet) Age-related Macular Degeneration | 04/24 | 06/25 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 350 | RoW | MRG002, Trastuzumab Emtansine for Injection | Shanghai Miracogen Inc. | Advanced Breast Cancer, Metastatic Breast Cancer | 09/23 | 10/23 | | |
NCT04836663: A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors |
|
|
| Recruiting | 2 | 90 | RoW | TQ-B3525 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer | 09/22 | 12/22 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
| Recruiting | 1 | 150 | RoW | GQ1005 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | HER2 Expressing or Mutated Advanced Malignant Solid Tumors | 12/24 | 07/25 | | |
NCT04257110: A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors |
|
|
| Active, not recruiting | 1 | 208 | US, RoW | BB-1701 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Locally Advanced/Metastatic HER2 Positive Solid Tumors | 08/24 | 12/24 | | |
| Active, not recruiting | 1 | 297 | RoW | FS-1502 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Solid Tumor, Breast Cancer | 04/24 | 06/25 | | |
NCT05339685: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M02D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 12/24 | 12/24 | | |
NCT05461768: A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M07D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Locally Advanced or Metastatic Solid Tumor | 06/25 | 12/25 | | |
